Prognostic evaluation of Acinetobacter baumannii ventilator-associated pneumonia in COVID-19.
Infez Med
; 30(4): 570-576, 2022.
Article
in English
| MEDLINE | ID: covidwho-2164892
ABSTRACT
Background:
Since the emergence of the pandemic of SARS-CoV-2, a high reported incidence of VAP in COVID-19 sustained by carbapenem resistant Acinetobacter baumannii (CRAB) has been observed, but data are scarce to date. Materials andmethods:
We retrospectively collected COVID-19 patients who developed CRAB-VAP - defined according to Center for Diseases Control (CDC) 2020 criteria and European Society of Clinical Microbiology and Infectious Diseases (ESCMID) or Infectious Diseases Society of America (IDSA) guidelines - to describe characteristics and outcome.Results:
Among 21 patients with CRAB-VAP in COVID-19, median age was 66 years (IQR 41-80). Median time of VAP-onset was 7 days (IQR 0-28 days) from ICU - admission and 76.2% had septic shock. Treatment regimens were all colistin-based, in 28% (n=6) including ampicillin/sulbactam and rifampicin. In three cases, cefiderocol was started as rescue. Survival rate at 28-days was 35% (n=7).Conclusion:
Non-fermenting Gram-negative bacteria are an emerging aetiology of VAP in COVID-19 patients. This underscores the urgent need for proper microbiological identification to address therapies and infection control protocols.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Etiology study
/
Experimental Studies
/
Observational study
/
Prognostic study
Language:
English
Journal:
Infez Med
Journal subject:
Allergy and Immunology
Year:
2022
Document Type:
Article
Affiliation country:
Liim-3004-12
Similar
MEDLINE
...
LILACS
LIS